May Cho
Hematology & Oncology · Orange, CANPI 1619263514
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $202,277 of the $334,281 with a category attached, or 60.5%. It is spread thinly across 33 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $129,931 and has fallen 99.7% since, to $348 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $903.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$77K
- Seagen Inc.$69K
- Helsinn Therapeutics (U.S.), Inc.$63K
- Taiho Oncology, Inc.$24K
- Daiichi Sankyo Inc.$23K
- Eisai Inc.$19K
- plus $59K from 27 others
Across 402 payments — averaging $6846.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Incyte Corporation$1M
- Seagen Inc.$308K
- E.r. Squibb & Sons, L.L.C.$52K
- AbbVie$46K
- Beigene, Ltd.$40K
- plus $67K from 2 others
What the payments were for
- Consulting fees$82,22225%
- Speaking & faculty fees$202,27761%
- Travel & lodging$37,23011%
- Food & beverage$12,4844%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $77,101 |
| Seagen Inc. | 54 | $68,587 |
| Helsinn Therapeutics (U.S.), Inc. | 49 | $63,432 |
| Taiho Oncology, Inc. | 35 | $23,739 |
| Daiichi Sankyo Inc. | 25 | $23,192 |
| Eisai Inc. | 27 | $19,089 |
| Exelixis Inc. | 36 | $13,395 |
| Pfizer | 5 | $10,235 |
| Astellas Pharma US Inc | 11 | $7,573 |
| E.r. Squibb & Sons, L.L.C. | 12 | $6,519 |
| Incyte Corporation | 12 | $6,428 |
| Genentech USA, Inc. | 5 | $3,054 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,880 |
| Amgen | 8 | $2,397 |
| Bayer | 2 | $1,804 |
| Astrazeneca UK Limited | 3 | $1,471 |
| Array Biopharma Inc | 3 | $932 |
| Bristol Myers Squibb | 1 | $600 |
| Astrazeneca AB | 3 | $323 |
| Intera Oncology, Inc | 1 | $267 |
| Genentech, Inc. | 3 | $238 |
| Lilly USA, LLC | 3 | $160 |
| Sirtex Medical Inc | 1 | $157 |
| Immunocore Limited | 1 | $145 |
| Foundation Medicine, Inc. | 1 | $116 |
| Novartis | 1 | $110 |
| GSK | 1 | $82 |
| Coherus Oncology, Inc. | 1 | $75 |
| Janssen Scientific Affairs, LLC | 1 | $54 |
| Medtronic | 1 | $53 |
| Karyopharm Therapeutics Inc. | 1 | $50 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$67,105
- TRUSELTIQ$62,649
- TUKYSA$52,675
- Lonsurf$23,253
- Enhertu$22,609
- LENVIMA$16,454
- TIVDAK$12,670
- Cabometyx$12,220
- BRAFTOVI$10,935
- OPDIVO$4,024
- TECENTRIQ$2,894
- ONIVYDE$2,880
- Vectibix$2,301
- Stivarga$1,713
- Intera 3000 Implantable Pump$267
- SIR-Spheres Microspheres$157
- KIMMTRAK$145
- FOUNDATIONONE LIQUID CDX$116
- KISQALI$110
- PIQRAY$110
How this compares
$334,281 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Orange
- Catherine CoombsOrange$786K
- Arash Rezazadeh KalebastyOrange$516K
- Misako NagasakaOrange$507K
- Elizabeth BremOrange$335K
- Angela FleischmanOrange$255K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.